Clinical Trial: NCT04328844
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | iOnctura |
| Information Provided By: | iOnctura |
| Last Update Posted: | 2026-07-08 |
Study Overview
Brief Summary
The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients both as monotherapy and in combination pemetrexed/cisplatin/avelumab (Part B Mesothelioma and NSCLC 1st line), in combination with avelumab (Part B Cutaneous Melanoma and NSCLC 2nd/3rd line) and ruxolitinib (Part B Primary Myelofibrosis)
Official Title
Conditions
Intervention / Treatment
- Drug: IOA-244
- Drug: Avelumab Injection
- Drug: Pemetrexed
- Drug: Cisplatin
- Drug: Ruxolitinib
Other Study ID Numbers
- IOA-244-101
- 2019-000686-20
- 2019
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | iOnctura |
| Information Provided By: | iOnctura |
| Last Update Posted: | 2026-07-08 |
Study Overview
Brief Summary
The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients both as monotherapy and in combination pemetrexed/cisplatin/avelumab (Part B Mesothelioma and NSCLC 1st line), in combination with avelumab (Part B Cutaneous Melanoma and NSCLC 2nd/3rd line) and ruxolitinib (Part B Primary Myelofibrosis)
Official Title
Conditions
Intervention / Treatment
- Drug: IOA-244
- Drug: Avelumab Injection
- Drug: Pemetrexed
- Drug: Cisplatin
- Drug: Ruxolitinib
Other Study ID Numbers
- IOA-244-101
- 2019-000686-20
- 2019